Seres Therapeutics (NASDAQ:MCRB) Azioni

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

News

MCRB

Seres Therapeutics Presents New SER-155 Biomarker Data At ASCO 2025, Highlighting Immune Reconstitution Potential

WIIM

Seres Therapeutics shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Chardan Capital analyst Keay Nakae downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Buy to Neutral but raised the price target from $1.25 to $6. Seres Therapeutics shares closed at $8.29 on Wednesday. <a href="https://www.benzinga.com/quote/mcrb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Susan Anderson downgraded Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Buy to Hold and lowered the price target from $8 to $5. Coty shares closed at $4.57 on Wednesday. <a href="https://www.benzinga.com/quote/coty/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) from Overweight to Neutral and slashed the price target from $42 to $32. Axalta Coating shares closed at $31.69 on Wednesday. <a href="https://www.benzinga.com/quote/axta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Jason McCarthy downgraded the rating for Theriva Biologics, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) from Buy to Hold. Theriva Biologics shares closed at $0.81 on Wednesday. <a href="https://www.benzinga.com/quote/TOVX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying COTY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08083338/image-2-33-1024x587.png" alt="" class="wp-image-907837" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08083338/image-2-33-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08083338/image-2-33-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08083338/image-2-33-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08083338/image-2-33.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AXTA

COTY

TOVX

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt raised Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) price target from $80 to $95. Rosenblatt analyst Mike Genovese maintained a Buy rating. Coherent shares closed at $69.62 on Wednesday. See how other <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">analysts view this stock</a>.</li>
<li>Chardan Capital boosted the price target for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from $1.25 to $6. Chardan Capital analyst Keay Nakae downgraded the stock from Buy to Neutral. Seres Therapeutics shares closed at $8.29 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">view this stoc</a>k.</li>
<li>Needham cut Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) price target from $55 to $50. Needham analyst Mayank Tandon maintained a Buy rating. Genpact shares closed at $49.55 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/G/analyst-ratings">view this stoc</a>k.</li>
<li>HC Wainwright &amp; Co. slashed the price target for Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) from $115 to $100. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Korro Bio shares closed at $13.93 on Wednesday. <a href="https://www.benzinga.com/quote/KRRO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for Holley Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NASDAQ">HLLY</a>) from $4.5 to $2.75. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Holley shares closed at $1.77 on Wednesday. <a href="https://www.benzinga.com/quote/HLLY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased Paycom Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) price target from $224 to $246. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Paycom Software shares settled at $228.67 on Wednesday. <a href="https://www.benzinga.com/quote/payc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $90 to $100. Needham analyst Bernie McTernan maintained a Buy rating. Uber shares closed at $83.65 on Wednesday. <a href="https://www.benzinga.com/quote/uber/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jones Trading cut Greystone Housing Impact Investors LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHI#NYSE">GHI</a>) price target from $15 to $3.5. Jones Trading analyst Jason Weaver maintained a Buy rating. Greystone Housing Impact Investors shares closed at $11.39 on Wednesday.  <a href="https://www.benzinga.com/quote/ghi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt slashed the price target for Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) from $18 to $15. Rosenblatt analyst Steve Frankel maintained a Buy rating. Sonos shares settled at $8.97 on Wednesday. <a href="https://www.benzinga.com/quote/sono/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) price target from $33 to $30. Needham analyst Bernie McTernan maintained a Buy rating. Unity Software shares closed at $20.66 on Wednesday. <a href="https://www.benzinga.com/quote/u/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UBER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08080339/image-2-32-1024x560.png" alt="" class="wp-image-907776" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08080339/image-2-32-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08080339/image-2-32-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08080339/image-2-32-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08080339/image-2-32.png 1151w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

COHR

HLLY

KRRO

PAYC

SONO

UBER

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Buy to Neutral and raises the price target from $1.25 to $6.

Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $0.12 by 3025 percent. This is a 1488.89 percent increase over losses of $(0.27) per share from the same period last year.

Earnings

Earnings Beats

Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday.
Shares of Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/DGX/earnings">better-than-expected first-quarter earnings.</a>
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
Quest Diagnostics shares jumped 7.3% to $173.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 15% to $6.39. PureCycle announced the sale of approximately $30 million in revenue bonds.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 15% to $13.36. Hesai introduced Infinity Eye, which will be available in three tailored versions A, B, and C. Each one caters to different levels of autonomous driving from basic assisted features to full automation.</li>
<li>NovaGold Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NG#NYSE">NG</a>) gained 14.7% to $3.5697 after the company and Paulson Advisers agreed to acquire Barrick&#8217;s 50% stake in Donlin Gold, forming a new partnership to develop the project.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) surged 14.5% to $2.68.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 13.7% to $139.15 after the US finalized plans to impose tariffs on most solar cells imported from Southeast Asia.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) jumped 13.6% to $13.74. SolarEdge Technologies will report financial results for the first quarter, before market open on Tuesday, May 6.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares rose 13.5% to $27.97.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) jumped 13.1% to $37.59 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) jumped 12.2% to $8.52.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 11.1% to $6.99.</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) gained 11% to $238.84 after the company reported better-than-expected first-quarter financial results. The company also authorized a $3 billion buyback and raised is dividend.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) gained 10.5% to $8.27.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 8.8% to $1.22.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 8.8% to $213.04.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.3% to $84.70 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) shares gained 6.8% to $134.63 after the company reported better-than-expected first-quarter financial results.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 5.8% to $195.64 after the company reported better-than-expected first-quarter EPS and revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44922024/how-to-earn-500-a-month-from-philip-morris-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Philip Morris Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

BTDR

BULL

CALX

CIFR

FSLR

HSAI

RIOT

SEDG

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BSGM

CRIS

GOVX

HCTI

KRYS

NAOV

NERV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $1.25 price target.

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Goldman Sachs analyst Chris Shibutani maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Sell and lowers the price target from $1 to $0.75.

Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $0.75

Cash Runway As of&nbsp;December 31, 2024, Seres had&nbsp;$30.8 million&nbsp;in cash and cash equivalents. Based on the Company's current cash (including the $50 million installment payment received from Nestlé in January 2025), an anticipated second installment payment to be received from Nestlé in July 2025, transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026.

Seres Therapeutics Reported Q4 Net Loss From Continuing Operations Of $15.7M, Narrowing From A Year-Ago Loss Of $34.7M

<h3>Companies Reporting Before The Bell</h3>
• Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $11.76 million. 
• Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $28.55 million. 
• Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $15.80 million. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is expected to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $54.11 million. 
• Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) is expected to report earnings for its fourth quarter. 
• US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $4.54 million. 
• Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $37.36 million. 
• G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $807.11 million. 
• Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report earnings for its fourth quarter. 
• Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is projected to report quarterly loss at $0.16 per share on revenue of $13.39 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $8.67 million. 
• D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $2.23 million. 
• Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $81.68 million. 
• Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $204.70 million. 
• CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $27.99 million. 
• Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $50.53 million. 
• Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $10.26 billion. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $147.53 million. 
• Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is estimated to report earnings for its fourth quarter. 
• Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $499.61 million. 
• Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is projected to report quarterly loss at $0.49 per share on revenue of $142.21 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $25.15 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report earnings for its fourth quarter. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is expected to report earnings for its fourth quarter. 
• Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $76.67 million. 
• Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is likely to report quarterly loss at $0.47 per share on revenue of $2.67 million. 
• Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter. 
• Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is estimated to report earnings for its fourth quarter. 
• Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly loss at $0.07 per share on revenue of $47.75 million. 
• Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $252.86 million. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $451.76 million. 
• Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $42.80 million. 
<h3>Companies Reporting After The Bell</h3>
• Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $394.49 million. 
• DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $761.31 million. 
• Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.08 per share on revenue of $130.60 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is likely to report quarterly earnings at $1.82 per share on revenue of $1.63 billion. 
• Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is expected to report earnings for its third quarter. 
• Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is likely to report quarterly loss at $0.35 per share on revenue of $118.90 million. 
• Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.10 per share on revenue of $10.37 million. 
• Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) is projected to report quarterly loss at $0.21 per share on revenue of $9.09 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is expected to report earnings for its fourth quarter. 
• Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is estimated to report quarterly earnings at $0.77 per share on revenue of $253.99 million. 
• Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is expected to report earnings for its fourth quarter. 
• Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.63 per share on revenue of $3.08 million. 
• Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $161.36 million. 
• FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is expected to report quarterly loss at $0.04 per share on revenue of $29.02 million. 
• aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) is projected to report earnings for its fourth quarter. 
• Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $142.61 million. 
• PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $7.70 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $108.91 million. 
• Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is expected to report quarterly loss at $0.18 per share on revenue of $12 thousand. 
• Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $2.77 million. 
• WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $46.00 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $250.17 million. 
• Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $276.46 million. 
• OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $92.09 million. 
• Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $30.77 million. 
• HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is estimated to report earnings for its fourth quarter. 
• Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $102.27 million. 
• AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is expected to report earnings for its fourth quarter. 
• PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is likely to report quarterly loss at $0.11 per share on revenue of $14.30 million. 
• Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is projected to report quarterly loss at $1.11 per share on revenue of $23.52 million. 
• Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $22.29 million. 
• Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $81.42 million. 
• ZOMEDICA CORP COM (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $8.10 million. 
• GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is projected to report quarterly loss at $0.11 per share on revenue of $42.21 million. 
• Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $40.13 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $119.53 million. 
• EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $170.48 million. 
• Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $36.08 million. 
• AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $74.60 million. 
• Origin Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $9.08 million. 
• Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $12.30 million. 
• Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is likely to report quarterly loss at $0.39 per share on revenue of $232.91 million. 
• Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $348.33 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its first quarter. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is estimated to report quarterly earnings at $7.13 per share on revenue of $3.47 billion. 
• Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.33 million. 
• Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $5.00 million. 
• Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $28.95 million. 
• BuzzFeed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZFD#NASDAQ">BZFD</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACTG

AFCG

AGRO

AKBA

ALLO

ALTI

APYX

ASPS

ATYR

AUID

AVAH

BAER

BEAT

BLDE

BLDP

BLNK

BZFD

CCLD

CION

CLLS

CLRB

CNTY

DLTH

DOCU

EVCM

EVOK

FEIM

FUTU

GIII

GRWG

GURU

HGBL

JYNT

LCUT

LRFC

MAPS

NOTE

NYXH

OPAL

ORGN

PANL

PESI

PHAR

PLBY

PRPL

PSQH

PTMN

QBTS

QNRX

RBRK

RGNX

SHIM

SKLZ

SMTC

SOHO

TACT

TBCH

TTAN

ULTA

USEG

VERI

VUZI

XNET

XPOF

ZSPC

ZUMZ

Earnings Scheduled For March 13, 2025

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock increased by 17.4% to $2.46 during Wednesday's after-market session. The market value of their outstanding shares is at $104.0 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock moved upwards by 16.23% to $2.65. The market value of their outstanding shares is at $2.7 million. As per the press release, Q4 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock increased by 12.64% to $0.8. The market value of their outstanding shares is at $18.4 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) shares moved upwards by 12.41% to $1.46. The company's market cap stands at $12.5 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 8.99% to $0.29. The company's market cap stands at $1.8 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock rose 8.19% to $0.75. The company's market cap stands at $128.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock decreased by 52.5% to $0.05 during Wednesday's after-market session. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares declined by 39.27% to $0.03. The company's market cap stands at $2.7 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 18.86% to $0.04. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares fell 9.98% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock declined by 9.76% to $3.7. The company's market cap stands at $115.1 million. As per the press release, Q4 earnings came out today. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.03% to $0.25. The company's market cap stands at $4.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

CPHI

CUTR

12 Health Care Stocks Moving In Wednesday's After-Market Session

Comments

Seres Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO